SHR-1210 plus GEMOX as first line treatment in biliary tract cancer: Results from a single-arm exploratory study. The prognostic role of soluble transforming growth factor-β related with soluble ...
Initial therapy with FOLFOXIRI plus bevacizumab (bev) for RAS mutant metastatic colorectal cancer (mCRC) and gene mutations in circulating tumor DNA (ctDNA) as a predictive marker for the efficacy: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback